CORC

在结果中检索

CORC

浏览/检索结果: 共44条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Exploring the concepts and practices of advanced breast cancer treatment: a narrative review 期刊论文
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 卷号: 9
作者:  Wang, Xiaojia;  Shao, Xiying;  Huang, Jian;  Lei, Lei;  Huang, Yuan
收藏  |  浏览/下载：38/0  |  提交时间：2021/06/15
Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2-Breast Cancer Patient With High Tumor Mutational Burden 期刊论文
FRONTIERS IN ONCOLOGY, 2021, 卷号: 10
作者:  Wang, Rong;  Yang, Yuchen;  Ye, Wei-Wu;  Xiang, Jianxing;  Chen, Songan
收藏  |  浏览/下载：43/0  |  提交时间：2021/04/26
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer 期刊论文
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 卷号: 9
作者:  Tian, Yiping;  Sun, Xiaohui;  Cheng, Guoping;  Ji, Enming;  Yang, Shifeng
收藏  |  浏览/下载：32/0  |  提交时间：2021/05/17
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:  Li, Qiao;  Guan, Xiuwen;  Chen, Shanshan;  Yi, Zongbi;  Lan, Bo
收藏  |  浏览/下载：15/0  |  提交时间：2020/07/01
Pertuzumab (P) as >= second-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience 期刊论文
ANNALS OF ONCOLOGY, 2019, 卷号: 30
作者:  Biskup, E. M.;  Sartorius, C. Montavon;  Mueller, A.;  Leo, C.;  Nussbaum, C. Uhlmann
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/06
OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文
2018, 卷号: 78, 期号: 13
作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan
收藏  |  浏览/下载：10/0  |  提交时间：2020/01/03
OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 会议论文
CANCER RESEARCH, 2018-07-01
作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan
收藏  |  浏览/下载：5/0  |  提交时间：2020/01/03
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) 期刊论文
Journal of Clinical Oncology, 2017, 卷号: 35
作者:  Robson M.E., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N., Delaloge S., Li W., Tung N.M., Armstrong A., Wu W., Goessl C.D., Runswick S., Conte P.F.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). 会议论文
作者:  Robson, Mark E.;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe;  Domchek, Susan M.
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/05
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC) 期刊论文
ANNALS OF ONCOLOGY, 2017, 卷号: 28
作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace